Yoshida, Masaki
Satake, Shosuke
Ishida, Kota
Tanaka, Yusuke
Ukai, Masashi http://orcid.org/0000-0002-7274-0126
Article History
Received: 6 August 2021
Accepted: 5 January 2022
First Online: 21 January 2022
Declarations
:
: Approval for this study was provided by a Central IRB (Pearl IRB, Indianapolis, IN, USA). All participants provided informed consent as an inclusion criterion. This was a non-interventional study based on data from two web-based questionnaires used in Japan and was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: MY: Daily allowances/lecture fees from Astellas Pharma Inc., Ferring Pharmaceuticals Co., Ltd., and Kissei Pharmaceutical Co., Ltd.; manuscript fee paid by Astellas Pharma Inc., and Kissei Pharmaceutical Co., Ltd.; research funding from Astellas Pharma Inc., and Taiho Pharmaceutical Co., Ltd.SS: Nothing to disclose outside of the presented work.KI, YT, MU: Employees of Astellas Pharma Inc.